On the morning of November 18th, "Chengdu Biocity PWC Industrial Investment Fund · In Vitro Diagnostic Industry Innovation and Entrepreneurship Forum" was held in Chengdu Frontier Medical Center. The forum focused on current hot topics for in-depth interpretation, aiming to understand the pain points and difficulties of in vitro diagnostics innovation and entrepreneurship, explore the advantages and breakthrough points of the development of in vitro diagnostic industry in Chengdu, promote the better and faster development of Chengdu’s in vitro diagnostic industry, and enhance the industrial cluster Ecological synergy.
This forum was co-sponsored by the Chengdu High-tech Zone Bioindustry Development Bureau and PricewaterhouseCoopers. More than 100 representatives of in vitro diagnostic innovation companies, investment and financing institutions, government agencies, and industry chain related experts participated in the discussion.
establishes a fund
introduces high-quality IVD projects into Chengdu High-tech Zone
in vitro diagnostics (IVD) is the largest sub-industry of the medical device industry, with a long industrial chain and value chain, with good public health value and industrial chain value. China's IVD industry is developing rapidly at a compound annual growth rate of over 15%. The output value is about to exceed 100 billion yuan, and the market demand is approaching a trillion yuan scale, attracting domestic and foreign IVD companies to rive out their strength.
Under the current background of a new development pattern in which domestic and international double cycles are the mainstay and the mutual promotion of domestic and international double cycles, how can domestic IVD companies seize opportunities for better development? Capital injection will undoubtedly bring greater power to enterprises.
As the main front of Chengdu's industrial development, Chengdu High-tech Zone took the lead in exploring, speeding up the research and development of characteristic financial products in the biological industry, and innovating to establish the first in vitro diagnostic (IVD) fund for the biomedical segment in Chengdu High-tech Zone-Chengdu Biocity Puhua Mike Industrial investment funds. The fund was established by the state-owned platform Biocity Company, a market-oriented fund, PricewaterhouseCoopers, and Mike Bio, a leading company in the in vitro diagnostic industry, in accordance with the principles of marketization, with a total scale of 1 billion yuan. According to the relevant person in charge of Chengdu Tianfu International Biological City Investment and Development Co., Ltd., the fund will combine with the policy support of Biological City, with the help of Pricewater Resources Capital’s resource integration capabilities and Mike’s bio-industry improvement capabilities, to screen and introduce high-quality IVD projects to Chengdu High-tech. District, accelerate the integration of the entire industry chain of the biological industry functional zone, provide comprehensive support for the overall development of Chengdu’s in vitro diagnostic industry, and achieve investment promotion. At present, 8 innovative start-up companies in the IVD field are about to land.
"Chengdu High-tech Zone has gathered a large number of medical device companies represented by Mike Biology, Aotai Medical, Hanchen Guangyi, New Health, Warvent, etc., and has initially established in vitro diagnostics, high-end imaging, high-value consumables, etc. The high-end medical device industry chain in the field." The relevant person in charge of the Bioindustry Development Bureau of Chengdu High-tech Zone said that during the "14th Five-Year Plan" period, Chengdu High-tech Zone will continue to focus on in vitro diagnostics, implanted interventional products and medical materials, medical imaging and treatment equipment , Functional diagnosis and treatment equipment and other high-end medical equipment fields, build high-value medical databases, and continue to promote the high-quality development of the medical equipment industry.
build a platform
to promote seniority exchanges and collaboration between government and enterprise
In order to give full play to the industry leading role of the strategic market-oriented industrial investment fund for in vitro diagnostics and enhance the exchange of in vitro diagnostics innovation and entrepreneurship within the domain, this forum also held project docking activities. At the event site, 9 domestic outstanding innovation projects in the field of in vitro diagnostics were exhibited offline and communicated with relevant local scientific research, financial, and government departments.
Chengdu Nuoen Gene Technology Co., Ltd., located in Tianfu Life Science Park, is a nucleic acid detection company focusing on the clinical application of micro nucleic acid detection. "The company’s original micro-nucleic acid miRFLP detection platform has the exclusive advantage of quantitative detection of micro-nucleic acids in trace samples. It surpasses existing detection technologies in sensitivity and accuracy, and is in a leading position in the world. The company has launched blood tests for liver damage and liver cancer. Micro-nucleic acid detection project, and peripheral blood/menstrual blood forensic evidence detection reagents, and a series of screening products such as tumor screening and major tissue damage detection will be launched successively, involved in China's huge medical diagnosis and molecular testing of public health management Market." The company's relevant person in charge said.
"I hope to use this opportunity to reach cooperation with more financial institutions and accelerate corporate development." Sairex (Shenzhen) Technology Co., Ltd. related person in charge said. It is reported that the company is committed to the research and development, production and global sales of advanced POCT detection technology. It has established a global R&D and marketing center in Shenzhen and a GMP factory in Suzhou.An enterprise approved by the FDA for the rapid test of new crown antibody emergency approval. The company has a completely self-patented homogeneous bioluminescence technology that can realize rapid, low-cost, and highly sensitive pathogen screening. "The company has launched a B round of financing to further support the development and production of POCT detection technology." The person in charge said.
"Hope to use this event as an opportunity to establish exchanges and collaborations among the government, enterprises, investment and financing institutions, activate the industrial atmosphere, optimize resource utilization and information sharing, promote the integration and linkage of the industrial chain, innovation chain, and financial chain, and build vitality The thriving Chengdu in vitro diagnostic industry is innovating a new ecology.” said the relevant person in charge of the Biological Industry Development Bureau of Chengdu High-tech Zone.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-